Intestinal Inflammation: Causes, Symptoms, and Treatment

Intestinal inflammation occurs when the gut’s immune system activates against the lining of the digestive tract, producing swelling, tissue damage, and a cascade of symptoms that extend well beyond the belly. The causes range from autoimmune misfires and genetic susceptibility to everyday environmental exposures like certain medications and food additives. The condition can be short-lived, as with an infection or a drug reaction, or it can become chronic, as in inflammatory bowel disease (IBD). Understanding what drives it, how to recognize it, and what treatment options exist involves pulling together threads from immunology, microbiology, genetics, and nutrition.

What Happens Inside the Gut Wall

Your intestinal lining is a single layer of specialized cells that does two contradictory jobs at once: it absorbs nutrients from food while keeping bacteria, toxins, and undigested material on the other side. These cells are held together by tight-junction proteins, and they secrete mucus and antimicrobial molecules that form a chemical shield over the surface. When either the physical barrier or the chemical shield breaks down, the gut becomes “leaky,” meaning the immune system suddenly encounters bacteria and other luminal contents it was never meant to see. That contact triggers immune activation, which plays a central role not only in IBD but also in liver diseases and colorectal cancer.¹

Once the barrier is compromised, the immune response can become self-reinforcing. Inflammatory signals recruit more immune cells, those cells release more destructive molecules, and the tissue damage worsens barrier function further. In a healthy person, regulatory mechanisms eventually dial this down. In someone with chronic intestinal inflammation, those brakes don’t work properly, and the cycle persists.

The Immune System’s Role

Intestinal inflammation is driven by a complex interplay between the innate immune system, which responds quickly and broadly, and the adaptive immune system, which is slower but highly targeted. A particular group of white blood cells, CD4+ T cells, sits at the center of this process. These cells come in several subtypes: some are pro-inflammatory (Th1, Th2, Th17, and Th9 cells), and others are regulatory (Tregs) and work to suppress inflammation. When the balance tips toward the pro-inflammatory subtypes, the gut becomes inflamed.²

These different T cell subtypes communicate through signaling molecules called cytokines. The specific mix of cytokines present at a given moment determines whether inflammation ramps up, spreads, or recedes. Cytokine levels shift over time and across different locations in the gut, which is why IBD can flare in one region while sparing another, and why the disease waxes and wanes unpredictably.³ Many modern drug treatments for IBD work by blocking specific cytokines or the pathways that produce them.

Common Causes and Triggers

No single cause explains intestinal inflammation. In most people with chronic disease, it emerges from a collision of genetics, immune quirks, gut bacteria, and environmental exposures.

Genetic Susceptibility

Over the past two decades, large-scale genetic studies have identified more than 200 genes associated with IBD risk.⁴ These genes span a range of functions: some govern the barrier itself, others affect how immune cells develop or respond to bacteria, and still others influence how the gut repairs itself after injury. Having a genetic predisposition doesn’t guarantee you’ll develop IBD, but it lowers the threshold at which environmental triggers can push the immune system into a chronic inflammatory state.⁵

The Microbiome

Your gut is home to trillions of bacteria, and their composition matters enormously. Certain beneficial bacteria ferment dietary fiber into short-chain fatty acids, which help nourish the gut lining, reduce inflammation, and support immune regulation.⁶ When the microbial community shifts out of balance, a state called dysbiosis, these protective metabolites drop and pro-inflammatory species gain a foothold. The microbiome also shapes T cell development, meaning that dysbiosis can directly worsen the immune imbalance described earlier.²

Medications and Food Additives

Nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen and diclofenac are a well-recognized trigger of intestinal inflammation, which is ironic given their name. These drugs can directly alter the composition of the gut microbiota and disrupt normal gut function.⁷ In lab and animal studies, diclofenac has been shown to increase mast cell numbers in the gut wall, which in turn damages tight-junction proteins and makes the intestinal lining more permeable.⁸

Certain food additives have also come under scrutiny. Dietary emulsifiers, which are used in processed foods to improve texture and shelf life, can alter the gut microbiota in ways that promote inflammation. Research using human gut microbiota samples found that carrageenans and various gum compounds had notably harmful effects, changing microbial density and composition while increasing the expression of pro-inflammatory molecules.⁹ This is still an active area of investigation, but it adds to the picture of how the modern processed diet may contribute to rising rates of intestinal inflammation worldwide.

Types of Intestinal Inflammatory Disease

When people hear “intestinal inflammation,” they usually think of IBD, which itself has two main forms. Ulcerative colitis (UC) involves continuous inflammation of the innermost lining of the colon and rectum. Crohn’s disease (CD) can affect any part of the digestive tract, from mouth to anus, and the inflammation tends to be patchy, sometimes burrowing through the full thickness of the bowel wall. These distinctions matter for treatment, since the drugs, dietary approaches, and surgical options differ depending on where and how deeply the inflammation sits.

A third, less well-known condition is microscopic colitis. The colon looks completely normal during a standard colonoscopy, and inflammation is only visible under a microscope. It comes in two subtypes, collagenous colitis and lymphocytic colitis, which produce the same symptoms: chronic, watery, non-bloody diarrhea.¹⁰ Microscopic colitis is frequently missed because the colonoscopy appears clean if biopsies aren’t taken, so it’s worth knowing about if you have unexplained chronic diarrhea.

Symptoms Beyond the Gut

The hallmark symptoms of intestinal inflammation are the ones you’d expect: abdominal pain, diarrhea, and rectal bleeding. In ulcerative colitis, rectal bleeding and bloody diarrhea are especially common presenting features.¹¹ Fatigue, weight loss, and urgency to use the bathroom are also frequent complaints.

What surprises many people is that IBD often shows up outside the gut entirely. Joints, skin, and eyes are the most frequently affected organs.¹² In a large study of over 2,200 IBD patients, roughly one in six had at least one extraintestinal manifestation. Joint problems were the most common, affecting about one in ten patients, followed by mouth ulcers and skin conditions.¹³

Even the lungs can be involved. While overt pulmonary disease has traditionally been thought rare in UC, recent research suggests that subclinical airway abnormalities may be present in 40 to 60 percent of cases, even when there are no breathing symptoms.¹⁴ These extraintestinal manifestations underscore that IBD is a systemic inflammatory disease, not just a gut problem.

How Intestinal Inflammation Is Diagnosed

Getting from symptoms to a firm diagnosis usually involves a combination of lab tests, imaging, and endoscopy with tissue biopsies. One of the most useful screening tools is a stool test for fecal calprotectin, a protein released by inflamed white blood cells in the gut. It correlates well with the degree of intestinal inflammation and is particularly good at distinguishing IBD from irritable bowel syndrome (IBS), which can produce overlapping symptoms like cramping and diarrhea but does not involve actual tissue inflammation.¹⁵

Fecal calprotectin isn’t just useful at diagnosis. It’s also used to track disease activity over time, guide treatment decisions, and predict relapses. In pediatric Crohn’s disease, for example, calprotectin levels correlate with endoscopic disease severity, and specific thresholds help clinicians gauge whether a child is in remission or heading toward a flare.¹⁶ Endoscopy with biopsy remains the gold standard for confirming a diagnosis, but calprotectin lets clinicians monitor inflammation without repeatedly scoping the patient.

Researchers are also investigating blood-based markers that could eventually complement stool tests. Early-stage work on markers like MMP9 and DPP4/CD26 has shown moderate ability to distinguish between mild and moderate ulcerative colitis, though these haven’t yet entered routine clinical use.¹⁷

Drug Treatments

Treatment for intestinal inflammation generally follows a stepwise approach, starting with milder therapies and escalating to stronger ones as needed.

Mesalamine for Mild to Moderate Disease

For mild to moderate ulcerative colitis, mesalamine (also known as 5-ASA) has been a first-line therapy for decades. It works locally in the gut, reducing inflammation in the intestinal lining by lowering the production of inflammatory signaling molecules.¹⁸ It can be taken orally, as a rectal suppository, or as an enema, and it’s especially valued for maintaining remission once a flare has been controlled.¹⁹ Newer formulations and drug-delivery technologies are being developed to improve how well mesalamine reaches the inflamed tissue and to extend its action beyond traditional anti-inflammatory pathways into areas like oxidative stress control.²⁰

Biologics, Immunomodulators, and Combination Approaches

When mesalamine isn’t enough, or when the disease is moderate to severe from the start, clinicians turn to corticosteroids for short-term flare control, immunomodulators like azathioprine for longer-term suppression, and biologic therapies that target specific immune molecules. Anti-TNF drugs like infliximab were the first biologics used in IBD and remain widely prescribed. More recently, drugs targeting other pathways have expanded the toolkit.

A challenging reality is that a meaningful subset of IBD patients don’t respond adequately to any single advanced therapy. For these refractory cases, a growing body of evidence supports combining different classes of drugs rather than simply switching from one to the next. The strategy of pairing a biologic with a small-molecule drug like a JAK inhibitor can sometimes consolidate partial responses that neither drug achieved alone.²¹ Real-world data from centers using these combination approaches in refractory IBD has shown favorable results without an increase in severe side effects, though the approach doesn’t work for everyone.²²

Dietary Therapy

Diet isn’t just a supportive measure in intestinal inflammation; in certain situations it functions as a primary treatment. Exclusive enteral nutrition (EEN), a liquid-only formula diet used for a set period, is now considered first-line therapy at many centers for inducing remission of active Crohn’s disease, particularly in children.²³ The approach works not just by providing nutrition but by actively reducing intestinal inflammation, likely through effects on the gut microbiota and mucosal healing.²⁴

Researchers are now exploring whole-foods-based versions of EEN. In children with active Crohn’s, a diet designed to replicate the effects of commercial formula but using real food induced remission and produced broad changes in metabolites found in stool, urine, and blood, suggesting it influences different metabolic pathways than the standard formula.²⁵ This is an encouraging direction because standard EEN is effective but notoriously difficult for patients to stick with, since it means consuming nothing but liquid formula for weeks.

When Surgery Becomes Necessary

Despite advances in drug therapy, surgery remains part of the treatment landscape. In ulcerative colitis, removal of the colon and rectum is curative, because the disease is confined to the large intestine. For Crohn’s disease, surgery isn’t curative since the disease can recur in other parts of the gut, but it may still be needed to address complications like strictures (narrowed segments of bowel), fistulas (abnormal tunnels between organs), or abscesses. Strictureplasty, a procedure that widens narrowed bowel segments without removing them, remains an effective option for selected small-bowel strictures and helps preserve intestinal length.²⁶

The decision to operate is rarely simple. In Crohn’s disease especially, the goal is to keep as much bowel as possible while addressing the complications that medications can’t resolve. Many patients with Crohn’s will have at least one surgery during their lifetime, and the timing of that surgery relative to medical therapy is an active area of clinical discussion.

The Gut-Brain Connection

People with intestinal inflammation frequently report anxiety, depression, and cognitive difficulties, and this isn’t just a psychological reaction to living with a chronic illness. The gut and the brain communicate through a two-way signaling network involving nerves, hormones, immune molecules, and microbial metabolites.²⁷ Inflammation in the gut sends signals that can alter brain function, and stress and mood changes in the brain can, in turn, worsen gut inflammation. Recent molecular research has begun to map the specific pathways through which inflammatory signals cross between the two organs.²⁸

This bidirectional relationship helps explain why psychological stress often precedes IBD flares, and why effective treatment of gut inflammation sometimes improves mood and cognition. It also suggests that addressing mental health as part of IBD management isn’t a luxury; it may genuinely affect disease outcomes.

A Rising Global Burden

Intestinal inflammatory diseases are becoming more common worldwide, and the pattern follows industrialization. In Western countries, ulcerative colitis rates rose sharply in the 1960s and 1970s before leveling off. Crohn’s disease rates remain high in Canada and parts of Western Europe. Meanwhile, regions that historically had very low rates, including parts of Asia, Eastern Europe, South America, and Africa, are now seeing rapid increases in UC.²⁹

Researchers have proposed a four-stage model for how IBD evolves in a given population: emergence, acceleration of new cases, compounding prevalence as treated patients live longer, and eventual stabilization. As of the early 2020s, developing countries are in the emergence stage, newly industrialized countries are seeing accelerating incidence, and Western countries are dealing with compounding prevalence, meaning the total number of people living with IBD keeps growing even as the rate of new diagnoses has stabilized.³⁰ This pattern strongly implicates environmental and lifestyle factors tied to urbanization and Westernized diets.

Intestinal Inflammation in Children

When IBD strikes during childhood, it carries a unique set of concerns. Chronic inflammation during growth years can impair linear growth, and up to one in five children with IBD show short stature at diagnosis. The risk is highest in children with pre-pubertal onset, small-bowel involvement, persistent disease activity, and high cumulative steroid use.³¹ The growth impact is especially prominent in Crohn’s disease and tends to be most severe in children diagnosed under age ten.³²

Controlling inflammation early is the single most important step for protecting growth. Steroid-sparing approaches like EEN and anti-TNF therapy are preferred in pediatric practice partly because corticosteroids themselves suppress growth. Careful attention to iron, vitamin D, and zinc status is also essential, since chronic gut inflammation impairs absorption of these nutrients. Adolescents may additionally experience delays in pubertal development due to disrupted hormone signaling, which makes early and aggressive treatment in this age group all the more important.

Microbiome-Targeted Therapies on the Horizon

Given the central role of the gut microbiota, there’s intense interest in therapies that directly reshape the microbial community. Traditional approaches like probiotics, prebiotics, and antibiotics have shown limited success for IBD, but fecal microbiota transplant (FMT), which introduces a healthy donor’s bacterial community into the patient’s gut, has provided a proof of concept that targeting the microbiome can work.³³ The next generation of microbiome therapies includes rationally designed products composed of specific beneficial bacterial strains, sometimes called live biotherapeutic products. Early preclinical results have been promising, and clinical trials are underway. If these products prove effective, they could offer a fundamentally different approach to intestinal inflammation: rather than suppressing the immune system, you would restore the microbial environment that keeps it in balance in the first place.